 Shares of Kala Pharmaceuticals Inc. KALA quadrupled in very volatile trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug IND application for KPI-012, its treatment of persistent corneal epithelial defect PCED. With the acceptance, the company said late Tuesday that it is looking to initiate a Phase ... The post : Kala Pharmaceuticals stock rockets nearly 300 after FDA OKs IND application for PCED treatment appear... 